Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

Abstract

Glatiramer acetate (GA) is a disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) with several putative mechanisms of action. Currently, there is paucity ofin vivo human data linking the well-established peripheral immunologic effects of therapy with GA to its potential effects inside the central nervous system (CNS). Brain proton magnetic resonance spectroscopy (MRS) allows in vivo examination of axonal integrity by quantifying the resonance intensity of the neuronal marker N-acetylaspartate (NAA). In a pilot study to investigate the effect of GA on axonal injury, we performed combined brain magnetic resonance imaging (MRI) and MRS studies in 18 treatment naïve RRMS patients initiating therapy with GA at baseline and annually for two years on therapy. A small group of four treatment naïve RRMS patients, electing to remain untreated, served as controls. NAA/Cr was measured in a large central brain volume of interest (VOI) as well as the normal appearing white matter (NAWM) within the VOI. After two years, NAA/Cr in the GA-treated group increased significantly by 10.7% in the VOI (2.179±0.26 versus 1.969±0.24, P=0.03) and by 7.1% in the NAWM (2.239±0.26 versus 2.089±0.31, P=0.04). In the untreated group, NAA/Cr decreased by 8.9% at two years in the VOI (2.019±0.16 versus 1.839±0.21, P=0.03) and 8.2% in the NAWM (2.079±0.24 versus 1.909±0.29, P=0.03). Our data shows that treatment with GA leads to axonal metabolic recovery and protection from sub-lethal axonal injury. These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA.

Keywords

axonal injury glatiramer acetate interferon-beta magnetic resonance imaging multiple sclerosis neuroprotection spectroscopy

Get full access to this article

View all access options for this article.

References

Trapp BD , Peterson J , Ransohoff RM , Rudick R , Mork S , Bo L. Axonal transection in the lesions of multiple sclerosis . N Engl J Med 1998; 338: 278-285 .

Trapp BD , Ransohoff R , Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability . Curr Opin Neurol 1999; 3: 295-302 .

Arnold DL , Matthews PM , Francis G , Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease . Magn Res Med 1990; 14: 154-159 .

Matthews PM , De Stefano N , Narayanan S , Francis GS , Wolinsky JS , Antel JP et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis . Semin Neurol 1998; 18: 327-336 .

Bjartmar C , Battistuta J , Terada N , Dupree E , Trapp BD. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve . Ann Neurol 2002; 51: 51-58 .

Larsson HB , Christiansen P , Jensen M , Frederiksen J , Heltberg A , Olesen J et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis . Magn Res Med 1991; 22: 23-31 .

Matthews PM , Francis G , Antel J , Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis . Neurology 1991; 41: 1251-1256 .

Davie CA , Hawkins CP , Barker GJ , Brennan A , Tofts PS , Miller DH et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions . Brain 1994; 117: 49-58 .

Narayana PA , Doyle TJ , Lai D , Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volume-try in multiple sclerosis . Ann Neurol 1998; 43: 56-71 .

10.

Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis . Neurology 2002; 58: S3-S9 .

11.

Miller A , Shapiro S , Gershtein R , Kinarty A , Rawashdeh H , Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation . J Neuroimmunol 1998; 92: 113-121 .

12.

Aharoni R , Teitelbaum D , Leitner O , Meshorer A , Sela M , Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer-1 . Proc Natl Acad Sci USA 2000; 97: 11472-11477 .

13.

Miller DH , Barkhof F , Berry I , Kappos L , Scotti G , Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines . J Neurol Neurosurg Psychiatry 1991; 54: 683-688 .

14.

Bottomley PA. Spatial localization in NMR spectroscopy in vivo . Ann N Y Acad Sci 1987; 508: 333-348 .

15.

Barkhof F , Filippi M , van Waesberghe JH , Molyneux P , Rovaris M , Lycklama a Nijeholt G et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis . Neurology 1997; 49: 1682-1688 .

16.

van Waesberghe JS , Kamphorst W , De Groot CJ , van Walderveen MA , Castelijns JA , Ravid R et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability . Ann Neurol 1999; 46: 747-754 .

17.

Gran B , Tranquill LR , Chen M , Bielekova B , Zhou W , Dhib-Jalbut S et al. Mechanisms of immunomodulation by glatiramer acetate . Neurology 2000; 55: 1704-1714 .

18.

Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis . Pharmacol Toxicol 2003; 98: 245-255 .

19.

Wiesemann E , Klatt J , Sonmez D , Blasczyk R , Heidenreich F , Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells . J Neuroimmunol 2001; 119: 137-144 .

20.

Kim HJ , Ifergan I , Antel JP , Seguin R , Duddy M , Lapierre Y et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis . J Immunol 2004; 172: 7144-7153 .

21.

Comi G , Filippi M , Wolinsky J and the European/Canadian Glatiramer Acetate Study Group . European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol 2001; 49: 290-297 .

22.

Chen M , Valenzuela RM , Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor . J Neurol Sci 2003; 215: 37-44 .

23.

Ziemssen T , Kumpfel T , Klinkert WE , Neuhaus O , Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy . Brain 2002; 125: 2379-2380 .

24.

Lewin GR , Barde YA. Physiology of the neurotrophins . Annu Rev Neurosci 1996; 19: 289-317 .

25.

Thoenen H. Neurotrophins and neuronal plasticity . Science 1995; 270: 593-598 .

26.

Narayanan S , Caramanos Z , Arnold D. The effect of glatiramer acetate on axonal integrity in multiple sclerosis . Mult Scler 2004; 10: S256-S256 .

27.

De Stefano N , Matthews PM , Antel JP , Preul M , Francis G , Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability . Ann Neurol 1995; 38: 901-909 .

28.

Sarchielli P , Presciutti O , Tarducci R , Gobbi G , Alberti A , Pelliccioli GP et al. 1 H-MRS in patients with multiple sclerosis undergoing treatment with interferon ß-1a: results of a preliminary study . J Neurol Neurosurg Psychiatry 1998; 64: 204-212 .

29.

Kilinc M , Agildere M , Benli S , Can U. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled preliminary study . Mult Scler 2003; 9: S111-S111 .

30.

Narayanan S , De Stefano N , Francis GS , Arnaoutelis R , Caramanos Z , Collins DL et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon ß-1b . J Neurol 2001; 248: 979-986 .

31.

Parry A , Corkill R , Blamire AM , Palace J , Narayanan S , Arnold D et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis . J Neurol 2003; 250: 171-178 .

32.

Gonen O , Grossman R. The accuracy of whole brain N-acetylaspartate quantification . Mag Res Imaging 2000; 18: 1255-1258 .

33.

Urenjak J , Williams SR , Gadian DG , Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro . J Neurochem 1992; 59: 55-61 .

34.

Filippi M , Rovaris M , Rocca MA and the European/Canadian Glatiramer Acetate Study Group . Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes” . Neurology 2001; 57: 731-733 .

35.

van Walderveen MA , Barkhof F , Hommes OR , Polman CH , Tobi H , Frequin ST et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE (T1-weighted) spin-echo images . Neurology 1995; 45: 1684-1690 .